MaryAnn Go

A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Shang‐Fan Yu, Bing Zheng, MaryAnn Go et al. · Clinical Cancer Research · 2015 · 159 citations

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates

Leanna R. Staben, Stefan G. Koenig, Sophie M. Lehar et al. · Nature Chemistry · 2016 · 147 citations

Medicinal Chemistry, Antibody–drug Conjugates, Drug Targeting +8

FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

Kristi Elkins, Bing Zheng, MaryAnn Go et al. · Molecular Cancer Therapeutics · 2012 · 86 citations

Hematological Malignancy, Antibody–drug Conjugates, Medicine +15

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Dongwei Li, Kirsten Achilles Poon, Shang‐Fan Yu et al. · Molecular Cancer Therapeutics · 2013 · 83 citations

Immunology, Immunotherapeutics, Immunotherapy +17

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Elisabeth A. Lasater, Dhara N. Amin, Rajat Bannerji et al. · American Journal of Hematology · 2023 · 24 citations · Full text

Refractory Nhl, Immunology, Pathology +16